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Appendix 1 
Data sheet 
(Part I) 
Patient demographics 
I Refused: NONES 
Study Group: Intervention/Control 
Study Number: 
Sex: Male/Female 
Date of Birth: Age: 
Contact number: 
Date of admission: 
Date of discharge: 
Length of Stay (days): Living alone: Yes/No 
Date 5 days post discharge: Nursing help: Yes/No 
Date 90 days post discharge: Family support: Yes/No 
Usual GP: Help with medications: Yes/No 
GP contact number: Details: 
Smoking history: 
Alcohol history: 
Weight: 
Height: 
Reason for current admission: 
Number of unplanned hospital admissions in previous 12 months: 
Risk factors for inclusion 
> 60 years Yes/No 
Two chronic medical conditions requiring drug therapy Yes/No 
One of either: cardiac failure, IHD, COAD, diabetes mellitus Yes/No 
Four or more chronic medications Yes/No 
Discharged to southern Tasmania <50km from RHH Yes/No 
Medical/Surgical history 
4. Laboratory data 
DATE Normal 
Na+ 135-145 
K+ 3.5-5.0 
Creatinine 60-115 I 50-100 
Urea 2.7-7.8 
CRT Cl 70-110 
Alb 35-50 
ALP 40-115 
ALT <65 
GGT < 90 I< 55 
Bili <25 
Ca t+Adj 2.1 - 2.6 
Phospha 0.75-1.5 
Mgt+ 0.65 - 1.00 
CK < 180 
CKMB <16 
BSL 3-8 
HbAlc <7 
Cholesterol < 5.5 
TG <2.0 
Hb 125-165 I 113-150 
RBC 4.0 - 5.5 
MCV 85-90 
WBC 3.5-11.0 
Neut 1.5 - 7.5 
Plat 160 - 420 
L/Shift >O 
PTT 28 - 33 
INR < 1.2 
Warfarin dose 
ESR <15 
TSH 0.4-4.0 
FT4 10-24 
VitD 18-114 
Iron 11-27 
Transferr 2.1- 3.6 
Fe Satur 15-55 
Digoxin 1.1-2.6 
Phenytoin 40-80 
5 Medication history: 
Admission: 
Drug Dose Frequency 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Complementary medicines: 
Drug Dose Frequency 
1 
2 
3 
4 
5 
Discharge: 
Drug Dose Frequency 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Complementary medicines: 
Drug Dose Frequency 
1 
2 
3 
6. Home visit follow-up (5 DAYS) Date of visit: .......................... . 
(a) Detection of any drug related problems: Yes/No 
D R It dP bi rug eae ro em D . ti escnp on 
Drug allergy 
Poor compliance 
Excessive or insufficient dose 
Drug-drug interaction Significance of interaction 1: Level I, 2, 3, 4, 5 
Significance of interaction 2: Levell, 2, 3, 4, 5 
Significance of interaction 3: Levell, 2, 3, 4, 5 
Significance of interaction 4: Levell, 2, 3, 4, 5 
Total number of significant (Level 1,2) interactions: 
Drug-food interaction 
Drug availability (manufacturer) 
Drug given for no clinical reason 
Drug not given when clinically 
indicated 
Drug used not the safest or most 
efficacious 
Improper drug-level monitoring 
Improper route of administration 
Patient not responding to therapy 
Therapeutic contraindication 
Patient duplicating medications 
Dispensed incorrect drug or strength 
Potential to over-medicate because 
of hoarding medications 
Patient using drug delivery system 
incorrectly 
Taking discontinued medication 
Unable to open containers 
Difficulty getting prescription from 
GP or taking to pharmacy 
Other 
(b) How many regular medications is the patient currently consuming? 
Drug Dose Frequency 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
c 1 t omp emen ary me di . cmes: 
Drug Dose Frequency 
1 
2 
(c) Is the patient being co-prescribed a NSAID and an ACE inhibitor/All-antagonist? 
Yes 
Angiotensin converting enzyme 
inhibitor/ Angiotensin II receptor antagonists 
Non-steroidal anti-inflammatory (NSAID) 
ACE Inhibitor/All-antagonist and NSAID 
(d) About how often would you say you forget to take your medications? 
Once a day 
Once a week 
More than once a week 
Once a month 
Rarely 
Never 
Compliance Check: 
(e) Was it deemed necessary for a Dosette box to be supplied? 
(f) Have you seen your GP since discharge from hospital? 
(g) Have you made an appointment to see your GP? 
(h) Did the GP/Hospital have to be contacted during the visit 
Other Information (if required): 
Yes No 
No 
Yes/No 
Yes/No 
Yes/No 
Yes/No 
Yes/No 
Date of Visit: (90 days) .......................... . 
Re-admitted: YES/NO 
YES/NO 
D 
Date re-admitted: 
Drug Related: Length of Stay in hospital: 
D R It dP bi ru2 eae ro em . ti escr1p· on 
Drug allergy 
Poor compliance 
Excessive or insufficient dose 
Drug-drug interaction Significance of interaction 1: Level l, 2, 3, 4, 5 
Significance of interaction 2: Level l, 2, 3, 4, 5 
Significance of interaction 3: Levell, 2, 3, 4, 5 
Significance of interaction 4: Level 1, 2, 3, 4, 5 
Total number of significant (Level 1,2) interactions: 
Drug-food interaction 
Drug availability 
(manufacturer) 
Drug given for no clinical 
reason 
Drug not given when clinically 
indicated 
Drug used not the safest or 
most efficacious 
Improper drug-level 
monitoring 
Improper route of 
administration 
Patient not responding to 
therapy 
Therapeutic contraindication 
Patient duplicating 
medications 
Dispensed incorrect drug or 
strength 
Potential to over-medicate 
because of hoarding 
medications 
Patient using drug delivery 
system incorrect! y 
Taking discontinued 
medication 
Unable to open containers 
Difficulty getting prescription 
from GP or taking to pharmacy 
Other 
(b) How many regular medications is the patient currently consuming? 
Drug Dose Frequency 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
c 1 d". omp ementary me 1cmes: 
Dru~ Dose Frequency 
1 
2 
(c) Is the patient being co-prescribed a NSAID and an ACE inhibitor/All-antagonist? Yes/No 
Yes No 
Angiotensin converting enzyme 
inhibitor/ Angiotensin II receptor antagonists 
Non-steroidal anti-inflammatory (NSAID) 
ACE Inhibitor/ All-antagonist and NSAID 
( d) About how often would you say you forget to take your medications? 
Once a day 
Once a week 
More than once a week 
Once a month 
Rarely 
Never 
Compliance Check: 
(e) Was it deemed necessary for a Dosette box to be supplied? 
(f) Have you seen your GP since discharge from hospital? 
(g) Have you made an appointment to see your GP? 
(h) Did the GP/Hospital have to be contacted during the visit? 
Other Information (ifrequired): 
Yes No 
Yes/No 
Yes/No 
Yes/No 
Yes/No 
Appendix 2 
Information and consent form 
(Part I) 
Royal Hobart Hospital and University of Tasmania 
Pharmacy follow-up of patients discharged from hospital 
Information sheet 
The aim of this study is to investigate the usefulness of having a hospital pharmacist visit patients at home 
following discharge from hospital. The pharmacist, in consultation with the patient's doctor, will assist with 
any medication problems or queries. 
Consecutive patients are being randomly allocated to either an 'intervention' or 'control group'. There is a 
50:50 chance of being allocated to each group. Patients in the 'intervention' group will receive a 
pharmacist visit at home five days after discharge from hospital, with a further follow-up at 90 days after 
discharge from hospital. Patients in the 'control group' will only be visited at 90 days after discharge from 
hospital. The pharmacist will attempt to help with any medication problems or queries. All patients will 
receive their routine medical and nursing care. 
Also we will take information (age, relevant medical and surgical history) from your hospital medical 
records. This information will be kept strictly confidential, and only the researchers will have access to 
identifying data. 
It is intended that the results from this study will be useful in improving the management of hospitalised 
patients and the services of the Pharmacy Department. 
Further information can be obtained from George Taylor at the Royal Hobart Hospital (phone 62228799), 
or Greg Peterson at the University of Tasmania (phone 62262197). 
The project has received ethical approval from the Royal Hobart Hospital Ethics Committee. 
If you have any concerns of an ethical nature or complaints about the manner in which the project is 
conducted you can contact the Chair or Secretary of the Ethics Committee. 
Chair: Dr Rosalie Parton 62 228226 
Secretary: Ms Chris Hooper 62 228160 
Consent Form 
Royal Hobart Hospital and University of Tasmania 
Pharmacy follow-up of patients discharged from hospital 
1. I have read and understood the 'Information Sheet' for this study. 
2. The nature and possible effects of the study have been explained to me. 
3. I understand that the study involves the following procedures: 
A pharmacist visit at home five days after discharge from hospital, with a further follow-up at 
90 days after discharge from hospital. Patients in the 'control group' will only be visited at 90 
days after discharge from hospital. The pharmacist will attempt to help with any medication 
problems or queries. 
4. I have been informed that the results of the study may not be of any direct benefit to my medical 
management. 
5. Any questions that I have asked have been answered to my satisfaction. 
6. I agree that research data gathered for the study may be published provided that I cannot be 
identified as a subject. 
7. I agree to participate in this investigation and understand that I may withdraw at any time 
without affecting my medical care or relationship with the hospital, doctors, nursing staff and 
research investigators. 
Name of subject .................................................. Signature .................................... .. 
Date ................................................................... . 
Name of witness ................................................. Signature ..................................... . 
Address ........................................................................................................................ . 
Date ................................................................... . 
Statement by the researcher 
I have explained this study and the implications of participation in it to this volunteer and I 
believe that the consent is informed and that he/she understands the implications of 
participation. 
Name of researcher ....................................................................... . 
Signature of researcher ..... ......................... Date ........................................ .. 
Appendix 3 
Example letter to GP following home-visit 
(Part 1) 
Date 
Dear Dr :XXXX 
Your patient, Mrs H, has been recruited into a study of patients recently discharged from the Royal Hobart 
Hospital. The study simply aims to investigate the effect of follow-up of patients following hospital 
discharge at home on outcomes such as the unplanned re-admission rate to hospital. The study has been 
approved by the Royal Hobart Hospital's Research and Ethics Committees. All patients have given their 
informed consent to participate. 
Your patient's medications on admission to hospital (date) 
Drug Dose Freauency 
1 bendrofluazide (Aprinox) 5 mg (1 tablet) mommg 
2 amiodarone (Aratac) 200 mg (1 tablet) daily 
3 aspirin (Astrix) 100 mg (1 tablet) daily 
4 ipratropium (Atrovent) MDI 20 mcg (1 puff) twice a day 
5 irbesartan (A vapro) 150 mg (1 tablet) daily 
6 diltiazem (Cardizem) 180 mg (1 capsule) daily 
7 isosorbide mononitrate (Imdur) 120 mg (1 tablet) morning 
8 temazepam (Normison) lOmg (1 tablet) night 
9 paracetamol (Panamax) when required 
10 frusemide (Uremide) 80 mg ( 2 tablets) morning 
11 beclomethasone 250 mcg (Respocort) 500 mcg (2 puffs) twice a day 
MDI 
12 trimethoprim (Alprim) 300 mg (1 tablet) daily 
13 amoxycillin/ clavulanic acid 875/125 mg (1 tablet) twice a day 
(Augmentin Duo Forte) 
Your patient's medications on discharge from hospital (date) 
Dru2 Dose Frequency 
1 bendrofluazide (Aprinox) 2.5 mg (half a tablet) morning 
2 amiodarone (Aratac) 200 mg (1 tablet) morning 
3 aspirin (Astrix) 100 mg (1 capsule) morning 
4 diltiazem (Vasocardol) 180 mg (1 capsule) morning 
5 isosorbide mononitrate (Imdur) 120 mg (1 tablet) morning 
6 ipratropium (Atrovent) MDI 40 mcg (2 puff) twice a day 
7 beclomethasone 250 mcg (Respocort) 500 mcg (2 puffs) twice a day 
MDI 
8 calcium carbonate (Caltrate) 600 mg (1 tablet) twice a day 
9 aciclovir (Acyclo-V) 200 mg ( 1 tablet) three times a day 
10 clotrimazole 1% vaginal cream 1 application night (4 nights only) 
(Canesten) 
11 Coloxyl and Senna 2 tablets Twice a day 
I visited your patient approximately five days after they were discharged from hospital, as part of the 
study's follow-up. The following issues may warrant attention to better benefit your patient's condition(s) 
and I make the following suggestions for you to consider in the management of your patient. 
1. A vapro was ceased while Mrs H was in hospital and unfortunately she has continued 
to take this since her discharge. It was noted in her discharge summary that A vapro 
could be re-started by you providing her creatinine (Cr) did not increase. On admission, 
her Cr was 468mmol and this decreased to 23 lmmol at discharge. 
2. Aprinox dose was decreased from 5mg a day to 2.5mg a day, however, she was 
confused with labelling from a previous supply and has continued to take 5mg a day (1 
tablet) She also has difficulty splitting the tablet in half, so I have asked her son to do 
this. 
3. I note Mrs H also has a salbutamol inhaler and a glyceryl trinitrate spray (both not 
charted in hospital) that were out of date. She also had a poor understanding of her 
inhalers and when to use them. Furthermore, she demonstrated poor inhaler technique, 
despite education in hospital. I have provided her with a spacer to use. 
4. Mrs H appears to have been taking two brands of diltiazem (Cardizem and 
Vasocardol) since discharge and gets very confused when discussing generic 
medication. I have informed her community pharmacy to ensure one brand of 
medication is supplied. 
5. I have suggested Mrs Huse a Dosette box to manage her medications which she has 
embraced. I have taken the liberty to supply her with one and have supervised her filling 
it correctly. 
6. Mrs H has a nebuliser that appears to function well, although her supplies of 
salbutamol (Asmol) and iptratropium (Ipratrin) were mostly out of date!!! 
I have to instructed Mr H to cease taking the Avapro until she consults with you. 
I have removed all unwanted medications and educated her son, who lives nearby, on her 
medications. I have also informed Mrs H's local pharmacy of her medication problems 
and the need to be extremely vigilant when supplying her medications 
If you have any queries or issues you would like to discuss in relation to the home visit, please do not 
hesitate to contact me. 
I hope this information proves worthwhile in helping with the care of your patients. 
Regards, 
Mark N aunton 
Pharmacist and PhD Candidate 
Phone: 0408 993 069 I 62262190 
Email: Mark.Naunton@utas.edu.au 
Appendix 4 
Examples of home-visit interventions 
(Part I) 
• An 89-year-old woman, who lives alone, was admitted to the Royal Hobart Hospital with a primary diagnosis of paroxysmal 
atrial fibrillation. She had a past medical history of ischaemic heart disease, hypertension, breast cancer and cataracts. Her 
prescribed medications upon admission to hospital were as follows. 
Aspirin 100 mg each morning 
Diltiazem SR 240 mg each morning 
Famotidine 20 mg once a day 
Frusemide 40 mg each morning 
Glyceryl trinitrate spray sublingually when required 
Glyceryl trinitrate patch 10-mg/24 hr (Transiderm-Nitro 50 mg) apply each morning and remove at night 
Paracetamol 500mg - lg when required 
Hypromellose (Poly-Tears®) eye drops instil into each eye when required 
Sennosides A and B (Senokot®) tablets when required 
Tamoxifen 20 mg once a day 
At discharge, amiodarone (200 mg daily) had been commenced, frusemide had been ceased and the dosage of the glyceryl 
trinitrate patch had been increased to 15-mg/24 hr (Nitro-Dur 15 mg; apply each morning and remove each night). The patient 
was visited at home by a pharmacist 5 days after discharge from hospital and it was determined that the patient was using (i) 
glyceryl trinitrate transdermal patches cut in half, with a worsening of her angina since discharge and (ii) Poly-Tears eye drops 
that were out of date. 
• A 68-year-old woman was admitted to the Royal Hobart Hospital with unstable angina. She had a past medical history of 
ischaemic heart disease, hypertension, diverticular disease, polymyalgia rheumatica and osteoporosis. Her prescribed 
medications upon admission were as follows. 
Aspirin: 100 mg each morning 
Diltiazem: SR 240 mg each morning 
Frusemide: 40 mg each morning 
Glyceryl trinitrate spray: one spray under the tongue when required 
Isosorbide mononitrate: 30 mg each morning 
Omeprazole: 20 mg each morning 
Paracetamol 500 mg/Codeine phosphate 30 mg (Panadeine Forte): when required 
Paroxetine: 20 mg each morning 
Quinapril: 10 mg each morning 
Quinine sulfate: 300 mg each night 
Simvastatin: 20 mg each night 
At discharge, frusemide had been ceased and the dosage of the isosorbide mononitrate had been increased to 60 mg mane. The 
patient was visited at home by a pharmacist 5 days after discharge from hospital and it was noted that the patient was (i) using a 
salbutamol inhaler instead of a glyceryl trinitrate spray for angina, (ii) taking two brands of frusemide concomitantly, despite the 
drug being stopped in hospital, (iii) taking aspirin 300-600 mg tds pm for rheumatic pain and (iv) not receiving any therapy for 
osteoporosis. 
• An 84-year-old woman was admitted to the Royal Hobart Hospital with heart failure. She was subsequently discharged on 
16 medications, including frusemide, spironolactone, captopril, and celecoxib (which had been changed from diclofenac 
during the hospital stay). When visited at home by a pharmacist 5 days later, she was taking both diclofenac and celecoxib. 
• A 66-year-old male was admitted to the Royal Hobart Hospital with headache. He had a medical history that included 
Reiter' s syndrome, asthma, ischaemic stroke, heart failure, atrial fibrillation and hypothyroidism. This patient also suffered 
from a sulphur allergy. When visited by the pharmacist at five-days it was found that the patient was using a nebulised 
salbutamol eight times a day. In consultation with the patient's treating specialist it was decided that captopril be changed to 
enalapril to detect if the sulphur component in captopril was contributing to his high use of salbutamol. The patient indicated 
to the pharmacist via the phone that his usage ofnebulised salbutamol had halved. This patient was also taking IOmg of 
prednisolone daily and not receiving any preventative therapy against osteoporosis. After discussion with the patient and his 
general practitioner he was initiated on calcium supplementation, and vitamin D was also suggested to be added to his 
regimen considering his high-dose ofprednisolone, lack of weight-bearing exercise and low exposure to sunlight, although 
both the patient's general practitioner (and patient to a lesser extent) were not in favour of this addition because of the patient 
was already consuming multiple (15) medications. 
• A 76-year-old woman was admitted to the Royal Hobart Hospital following a collapse secondary to an arrhythmia. This lady 
suffering multiple medical problems including congestive heart failure, hypertension, atrial fibrillation, osteoarthritis, 
Meniere's disease and previous stroke was diagnosed with osteoporosis after sustaining her fall. Despite this, she was 
discharged without any treatment for her osteoporosis and little mention of it was made to her general practitioner. Her 
medications at discharge were: 
Warfarin: 4mg once a day 
Fosinopril: 20mg each morning 
Frusemide: 80mg twice a day 
Isosorbide mononitrate: 120mg each morning 
Diazepam: 5mg each night 
Prochlorperazine: 5mg three times a day for nausea 
Docusate sodium 50 mg, total sennosides (calculated as sennoside B) 8 mg: 2 tablets twice a day 
when required 
Glyceryl trinitrate spray: 1 spray under the tongue when required 
Doxepin: l 50mg each night 
Paracetamol 500mg: lg Q4H-Q6H strict 
Paracetamol 325mg/ Dextropropoxyphene 32.Smg: 2 tablets QID 
Digoxin: 125mcg daily 
Atenolol: 25mg daily 
Discussion with the patient's general practitioner resulted in regular calcium supplementation (because of poor dietary intake), 
vitamin D (essentially housebound) and raloxifene being added to her regimen. Her use of paracetamol was also rationalised. 
• A 65 year-old male was admitted to the Royal Hobart Hospital with confusion. He had been recently discharged from 
hospital following a minor stroke. He had a previous history of transient ischaemic attacks, ischaemic heart disease, 
hypercholesterolaemia and a TURP. It was also noted he suffered chronic obstructive pulmonary disease. His medications on 
discharge were: 
Aspirin: 1 OOmg daily 
Diltiazem: 240mg daily 
Simvastatin: 20mg each night 
Dipyridamole SR: 200mg twice a day 
Amlodipine: 5mg each morning 
Paracetamol: lg four times a day 
GTN spray: SIL when required 
Salbutamol inhaler: 2 puffs when required 
Beclomethasone: 250-µg Two puffs twice a day 
There were a number of issues identified in this patient upon the visit at day 5. Firstly it was discovered the patient was non-
compliant with all medications. In fact they were all in the original bag that he left with from the hospital. The patient had no 
understanding of any of his medications and appeared confused. The patient's general practitioner was called and it was decided 
the patient should be referred to community health nursing. The community health nurse commenced daily visits to the patient to 
supervise the patient and administer his medications. However he did not have any supervision for his evening medications. It 
was then discussed with the patient's general practitioner to change his simvastatin to atorvastatin, which could be taken in the 
morning. His dipyridamole was ceased and clopidogrel commenced in the morning. There was still the issue of his inhaled 
steroid medication, which was to be used morning and night. The patient's general practitioner reviewed his patient's notes 
suspecting that his patient didn't have a need for the airways disease medication at all. In fact after reviewing the patient's 
medical notes at the hospital it was discovered that there was a transcription error from a previous admission where the patient 
was initiated on inhaled steroids for suspected asthma after presenting to the emergency department with shortness of breath. The 
patient was later readmitted with angina symptoms and the inhaled steroids ceased. However when the patient was readmitted, 
the paramedics brought with the patient all the medications they found at his house including his inhaled medications. It was 
automatically and incorrectly assumed this patient was still using them and thus when his drug chart was written, it included his 
inhaled steroid and salbutamol. Hence, in view ofthis finding and the fact that the patient had never used an inhaler except when 
he was in hospital, the inhaled medications were ceased. 
• An 82 year-old male (living alone) was admitted to the Royal Hobart Hospital with chest pain. He had a history IHD 
(including two myocardial infarctions), chronic obstructive pulmonary disease, gout and bladder cancer. He was (not 
surprisingly) an ex-smoker and admitted regular alcohol consumption. His medications on discharge were: 
Salbutamol 5mg nebules: Use one nebule four times a day 
Ipratropium 500mcg nebules: Use one nebule four times a day 
Isosorbide dinitrate: 1 Omg twice a day 
Theophylline: 250mg twice a day 
Verapamil: 40mg twice a day 
Ranitidine: 150mg twice a day 
Allopurinol: IOOmg daily 
Coloxyl and Senna: two tablets twice a day 
Paracetamol: lg four times day 
Tramadol: 50mg four times a day 
Norfloxacin: 400mg twice a day 
The pharmacist visited this patient five-days post-discharge and found the patient's management of his medications in complete 
disarray. There were a number of problems identified with this patient. The patient was hoarding other medications and was 
confused with his discharge medications and the ones he had at home. He was found to be consuming Ibuprofen 400mg each 
morning instead of his allopurinol. He was in pain and had not taken any paracetamol and few tramadol capsules, in-fact he 
indicated he was using ranitidine for his pain, although this did not appear the case upon review of his medications. In addition 
he was using his nebuliser every two hours with little relief. He was found to be using ipratropium 250mcg instead of the 
500mcg he was receiving in hospital. During the visit the pharmacist tested his nebuliser and found that despite 20 minutes of 
continuous nebulising, very little of the drug was actually being vaporised and the machine and its accessories in need of urgent 
service. Further more this patient was found to have four different of inhalers, which were not used in hospital. It is important to 
point out here that the patient was discharged in a very stable condition with regards to his airways disease. This particular 
patient was using salmeterol MDI, fluticasone MDI, ipratropium MDI as well as a salbutamol MDI. It was evident that the 
patient was confused when to use each of these inhalers and he indicated to the pharmacist that he used the salmeterol and 
fluticasone when he was short of breath, in addition to using his Ventolin. The patient used a spacer but on inspection it was in 
need of urgent replacement. In addition his technique was poor. This patient had also consumed none of his antibiotic tablets. 
The situation can only be described as a medication management nightmare. It was obvious this patient's problems were not 
going to be resolved with one visit. 
It was arranged that the Royal Hobart Hospital respiratory nurse perform a follow-up visit (in consultation with the patient's 
general practitioner) to help sort out this patient's seemingly poor understanding of his airways disease and medications to treat 
it. The pharmacist contacted the patient's daughter to alert her of her father's mismanagement of medication and to involve her in 
the management of his medications. She was previously unaware of his poor control of medications. A Dosette box was provided 
and his community pharmacy was contacted to arrange filling on a weekly basis. The pharmacy was also asked to retain all 
repeats for his prescribed medications to prevent further hoarding. The patient's nebuliser was also substituted with a 
replacement from the Royal Hobart Hospital until it had been serviced. The patient's daughter also purchased a new spacer and 
accessories for the nebuliser. In consultation with his general practitioner, the inhaled fluticasone was ceased. The patient was 
also given re-instruction on how to use the spacer. 
It was pleasing to note that although this patient required hospitalisation during the 3-onth follow-up, upon the 90-day visit he 
had a much better understanding of his medications and compliance appeared excellent. He also used the correct technique when 
using his spacer and voluntarily admitted to using less salbutamol. The above case clearly demonstrates some common problems 
in the community due to poor understanding of medications; and how easily confused elderly patients can become with multiple 
medications. It certainly highlighted or stressed the need close monitoring of patients following discharge from hospital. Further 
examples of problems identified and resolved are listed below. 
• Patient discharged on frusemide 40mg twice a day. Patient complained that since discharge they were going to the toilet 
more frequently than in hospital and it was inconvenient. The general practitioner was contacted and the dose of frusemide 
was reduced to 20mg daily with successful results. 
• Patient discharged on sertraline 50mg daily. Patient was actually only taking lOOmg daily prior to hospital admission 
(patient assumed dose was decreased during hospital stay). The error occurred because the patient was prescribed sertraline 
1 OOmg tablets but on the label of the box stated to take half a tablet a day and during the emergency admission it was noted 
that the patient was taking half a sertraline 50mg tablet daily (instead of 1 OOmg). 
• Patient initiated on warfarin prior to their discharge from hospital and developed gout after discharge. Patient was found to 
be using a non-steroidal anti-inflammatory. Patient was instructed to cease 
• A patient's Dosette box was examined and found to have Isosorbide mononitrate 60mg missing. This patient had noticed an 
increase in their angina symptoms. 
• Patient indicated that their angina was not being relieved very well by the G1N spray, upon investigation it was found that 
the spray was out of date. 
• Patient was hospitalised for worsening COAD and was stabilised relatively quickly during their admission. Upon visiting the 
patient in their home they were found to be short of breath as before admission. After close inspection of the nebuliser and 
testing it, it was found that it was in need of urgent servicing and the accessories, due to very little drug being nebulised, 
despite the machine operating for 20 minutes. 
• Elderly patient was prescribed 1 Omg prednisolone daily for > 3 months and was not receiving any prophylactic medication 
against osteoporosis. 
• Patient had heart failure and not on an ACE inhibitor (no apparent contraindications to use). The patient's general 
practitioner was contacted and patient was initiated on an ACE inhibitor on a subsequent visit to the general practitioner. 
• Patient with ischaemic heart disease was discharged without aspirin therapy. In consultation with the medical team who 
were looking after the patient and the patient's general practitioner, aspirin 1 OOmg was commenced. 
• Patient taking atorvastatin for hypercholesterolaemia was found to be consuming grapefruit juice each morning. 
• Patient was confused with brands of medication. Patient was discharged with Cardizem ® ( diltiazem) and had V asocardol® 
( diltiazem) at home. This particular patient was using both brands because she forgot they were the same drug. 
• A patient was taking calcium carbonate tablets (Caltrate®) in the morning. Patient was consequently instructed to take at 
night for greater absorption. 
• Patient smoked 10 cigarettes a day. Patient had unsuccessfully given up smoking previously. Patient was counselled and 
instructed that bupropion (Zyban®) was available. Patient discussed the option with her general practitioner and 3 months 
later had still remained abstinent form smoking. 
• Patient had been on Premarin® (conjugated oestrogens) 300mcg prior to hospital admission, however while she was not 
given any further supplies at discharge she was still to be treated with it. This patient was confused and thought that because 
she was given no further supplies she was to stop taking it. 
• An elderly patient who was found to be non-compliant at the five-day visit was asked to show the pharmacist her 
medications. The pharmacist then discovered the patient was hoarding 46 unopened medications, many which were ceased 
medications and only recently purchased from a pharmacy. The patient claimed she rang her pharmacy and always asked for 
medications that they thought she needed. Her regular pharmacy was informed of the finding and given the current drug 
regimen. Her general practitioner was also made aware of the finding. 
• A patient was discharged on Persantin SR® 200mg once a day and told to increase to twice a day if tolerated. The patient 
was visited on day five and found to be intolerant of the twice-daily regimen. The patient had reverted to once daily dosage 
and did not see the need to discuss with his general practitioner the intolerance with twice daily administration. 
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Appendix 5 
Patient survey 
(Part I) 
Patient Satisfaction Questionnaire 
Please help us evaluate and improve the pharmacy service by answering some questions about the services 
you have received from the pharmacist, Mark Naunton. We are interested in your honest opinions, whether 
they are positive or negative. Please answer all of the questions. Thank you very much, we really 
appreciate your help. 
Please Tick your Answers 
1 How satisfied are you with the amount of contact you received from the pharmacist? 
o Quite dissatisfied 
o Indifferent or mildly dissatisfied 
o Mostly satisfied 
o Very satisfied 
2 Has the information and other services you received from the pharmacist helped you to deal more 
effectively with your medication? 
o Yes, they helped a great deal 
o Yes, they helped somewhat 
o No, they really didn't help 
o No, they seemed to make things worse 
3 Did you get the kind of information and other services you wanted from the pharmacist? 
o No, definitely not 
o No, not really 
o Yes, generally 
o Yes, definitely 
4 Is there other information you need about your medication but have not received? 
o Yes, there definitely is 
o Yes, I think there is 
o No, I don't think there is 
o No, there definitely is not 
5 Overall, how would you rate the quality of the service that you received from the pharmacist? 
o Excellent 
o Good 
o Fair 
o Poor 
6 Any comments? (Please use the back of this page if more space is required) 
Thank you. Please post in the reply-paid envelope supplied. 
Appendix 6 
Patients' comments 
(Part 1) 
1 "The service is excellent for senior citizens to learn about their tablets 
and was long overdue" 
2 "My questions were answered and I was quite happy with all help I 
have received - with thanks" 
3 "The pharmacist couldn't have been more obliging" 
4 "The pharmacist was very helpful" 
5 "Mark was very helpful" 
6 "I have found Mark to be a most obliging, conscientious in his work. 
Nothing is a trouble to him and he fully explains answers to any 
queries" 
7 "Mark has been very courteous and helpful. It has always been a 
pleasure to talk to him" 
8 "We were quite happy" 
9 "All Ok" 
10 ''very pleased with service" 
11 "Being able to have medication when needed" 
12 "I was very pleased with the help given to me" 
13 "Most helpful, thank you Mark" 
14 "Thank you Mark for your help" 
15 "Mr Mark Naunton is outstanding and is excellent at his job, more than 
helpful and greatly appreciated" 
Appendix 7 
Poster displayed in pharmacies 
(Part Ila) 

Appendix 8 
Newspaper editorial for osteoporosis 
screening (i) 
(Part Ila) 

Appendix 9 
Newspaper editorial for osteoporosis 
screening (ii) 
(Part Ila) 
FREE TESTING: Staff at Katie McNamara's Healthsense Pharmacy 
are waiting to take bookings for free osteoporosis testing at the High 
St premises. 
Free tests offer in bid 
to beat osteoporosis 
BOOK1NGS are now 
being taken for free os-
teoporosis testing at Ka-
tie McNamara's Health-
sense Pharmacy in New 
Norfolk. 
Osteoporosis affects 
about two million Aus-
tralians with one in two 
women and one in three 
men over the age of 60 
suffering an osteoporotic 
fracture. 
Osteoporosis is a con-
dition where bones be-
come brittle and can 
easily break. People are 
often unaware they have 
osteoporosis until they 
break a bone or have an 
X-ray performed. 
But efforts are being 
made to improve early 
detection and treatment 
of this common condi· 
tion. 
Mark Naunton, from 
the Tasmanian School of 
Pharmacy at the Univer-
sity of Tasmania, is us-
ing a portable ultra-
sound machine to assess 
women's risk for osteo-
porosis over the age of 
65. 
Mr Naunton is a phar· 
madst completing his 
PhD in pharmacy prac-
tice. His project is being 
supervised by Professor 
Gregory Peterson, from 
the School of Pharmacy, 
and Associate Professor 
Graeme Jones, a rheu-
matologist from the 
Menzies Centre. 
Mr Naunton said 
harmless sound waves 
------------. transmitted throtJgh a 
JENJAMIN TCE 
:WNORFOLK 
PHONE 
6261 3447 
patient's heel could . be 
µsed to assess their risk 
for osteoporosis. For the 
next three weeks he ·will 
perform free testing for 
local women over 65 to 
assess that risk. 
~o be conducted at th?. 
Derwent Valley Health-
sense Pharmacy, the test 
is completely painless 
and takes about 20 sec-
onds to complete. 
Emma Francis, a 
pharmaceutical repre-
sentative for Merck 
Sharpe and Dohme, has 
provided staff with 
T-shirts encouraging 
people to ask about os-
teoporosis and have the 
test performed. 
Women over the age of 
65 who would like a test 
can either call in to the 
pharmacy or phone on 
62612268 to make an 
appointment. Testing 
starts on Monday for 
three weeks only, 
Mr N aunton said 
women who book an ap-
pointment will also have 
their calcium intake as-
sessed free of charge. 
The results from the 
heel ultrasound tests 
can be sent to the pa-
tient's local doctor, all of 
whom had, been made 
aware of the testing. 
Appendix 10 
Data sheet 
(Part Ila) 
Name: 
Study#: Subject Data Sheet 
General Practitioner: 
1 Age: .......... Years 
2 a) Nationality: ................... Ethinic origin: ....................... . 
b) If you were not born in Australia, how long have you been here? ...... Years 
3 Your marital status: 
Married D De-facto D Divorced D Widowed D Single D 
4 Number of children? .................. . 
5 Highest education level? 
a) No formal schooling D 
b) Primary school D 
c) High school D 
d) Technical qualification D 
e) University D 
6 What is your height?......... Centimetres 
7 What is your weight? ......... Kilograms 
8 Current medications 
Medication Strength How many times a day 
PREVIOUS HRT USE:YES/NO 
Other risk factors for osteoporosis 
Yes No 
Have/did either of your parents broken/break a hip after a minor bump or 
fall? 
Have you broken a bone after a minor bump or fall after age 40? 
Did you undergo menopause before the age of 45? 
Have you taken corticosteroid tablets (cortisone, prednisolone etc) for 
more than 3 months? 
Have you lost more than 3cm (1 inch) in height? 
Do you regularly drink heavily (in excess of safe drinking limits)? 
Do you smoke more than 20 cigarettes a day 
Do you suffer frequently from diarrhoea (caused by problems such as 
coeliac disease or Crohn's disease)? 
Do you suffer from diabetes ? 
Do you suffer from rheumatoid arthritis? 
Food Frequency Questionnaire for Calcium Intake 
Milk 
1 How much milk in total do you usually use each day for yourself? (Please circle) 
None 300 to 600 mls 
Less than 150 mls 600 mls to 1 litre 
150 to 300 More than one litre 
2 If you eat breakfast cereal how much milk do you usually add? 
None 
~cup 
Y2 cup 
1 cup 
more than one cup 
3 How many cups of tea or coffee with milk do you usually drink each day? 
4 What type of milk do you usually drink? 
No milk 
Light milk 
Skim milk 
Whole milk 
Soy milk 
Other 
5 How much of the following foods do you eat each DAY? 
Food Type Amount per DAY Equivalents 
Example 
Wholemeal bread 7 slices per day 1 slice= 25g 
1 BREAD 
Wholemeal bread I I I slices 1 slice= 25g 
White bread or other I I I slices 1 slice= 25g 
2YOGHURT 
Natural yogurt I I I I lg 1 small carton = 200g 
Fruit yoghurt I I I I lg 1 tablespoon = 30g 
6 How much of the following foods do you eat each WEEK? 
Food Type Amount per WEEK Equivalents 
Example 
13 tablespoons per week 3 tablespoons = 60g 
Muesli 
1 CHEESE 
Hard/tasty cheese Q 1Slice=30g 
Soft/Cream/Cottage I I I slices 1 small carton = 250g 
2 ICECREAM 1scoop=50g 
g 
3EGGS large I I g or medium 1 large= 60g 
I I g 1 medium = 45g 
4FISH 
Tinned salmon g ~cup= 120g 
Tinned sardines g 4 - 5 sardines = 60g 
Prawns/Shrimps g 3 - 4 pieces = 60g 
Scallops g 5 - 6 = 90g 
White fish g 1 medium fillet = 1 OOg 
5 CEREAL FOODS 
Muesli g 3 tablespoons = 60g 
All Bran Cereal g 2 tablespoons = 1 Og 
Sweet biscuits biscuits 1 biscuit = 1 Sg 
Chocolate biscuits biscuits 1 biscuit = 1 Sg 
Plain cake slices 1slice=40g 
6 FRUITS I VEG I NUTS 
spinach/silver beet g Y2 cup= 60g 
Dried fruits g 1 tablespoons = 1 Sg 
Peanuts g 18-20 nuts = 1 Sg 
7 MISCELLANEOUS 
Chocolate I lg 4 squares = 20g 
Orange Juice glasses or mls 1 large glass = 200ml 
8ALCOHOL 
White wine glasses or mls 1 glass = 1 OOml 
Red wine glasses or mls 1 stubby = 375 ml 
Beer glasses or mls 1 glass = 200ml 
7 Do you take any calcium or multivitamin tablets? If yes please specify. 
8 Do you take any antacids or indigestion tablets? If yes please specify type, amount and 
frequency. 
The following questions are designed to assess your exposure to sunlight. 
9 How often do you go outside into the street or garden? 
Never 
Less than once a week 
One to two times a week one 
Most days 
10 Do you avoid direct sunshine? 
Always 
Usually 
Never 
11 Have you had a suntan in the last 6 months? 
No 
Slight tan 
Obvious tan 
Knowledge test 
The following statements require a "true" or "false" answer only (please tick box) 
True False 
One in two women and one in three men over 60 will develop an 
osteoporotic fracture 
Family history of osteoporosis is not a risk factor for osteoporosis 
Early menopause, such as after a hysterectomy, is not a risk 
factor for osteoporosis. 
A lifetime low intake of calcium will increase the risk of 
osteoporosis 
Smoking is not a risk factor for osteoporosis 
Thin women are more often affected by osteoporosis than heavy 
women 
Weight bearing exercise such as walking can help prevent 
osteoporosis 
After 40 it is too late for people to increase their calcium intake to 
prevent osteoporosis 
After menopause, osteoporosis may be slowed down by taking 
oestrogen 
All individuals lose bone mass after 40 years of age 
Normally bone loss slows down after menopause 
A diet high in calcium throughout life can help prevent 
osteoporosis 
Post-menopausal women need about 1000-1500mg of calcium 
each day 
Dairy products are a major source of calcium 
It is normal for bone loss to continue throughout life 
Active women are at higher risk for osteoporosis than inactive 
women 
Alcohol abuse is not linked to the incidence of osteoporosis 
Appendix 11 
Example of information from Osteoporosis 
Australia 
(Part Ila) 
What is Osteoporosis? 
Who is at Risk? 
.Osteoporosis 
What is osteoporosis? 
Osteoporosis is a condjtion wbere the bones 
become fragile-and brittle, and can, fracture 
n1ore easily than normal bones. 'Even minor 
falls can cause. serious fractures. 
I in 2 women and I in 3 men over 60 
will have a fracture( ctue to osleopprosis. 
Osteoporosil'. rmd fractures are rt1ajor c.auses 
tif injury, loi1g term disability and even death 
in older Aµstr~ljans .. 
How common is osteoporosis? 
The incidence of osteoporosis is increasing, 
primarily ns people live longer and the 
population ages. 
• It is predicted that by 20 I 0, I in 
3 hpspital beds will be dccupied 
by elderly won1en with fractures. 
( Dubbo Osteoporosis Epidemiology 
StiU/v) 
• It has been caJCulated that 'by 20 I I , 
hip fractures in Ausrra:H.a will have: 
increased by 83%. 
( Natio1tal kes11arch lnsfitute of. Geromology 
dnd'Geric(trk MediciM. Melboume) 
What causes osteoporosis? 
Osteoporosis is diffel'ent from mostuther 
diseases or common illnesses in that there is 
no one single cause. 
The ovcmll health of a person's bones is 
detcrmfocd by: 
• Your genes 
• Nutrition (especially calcium and 
vitamin D) 
• Hormonal activjty 
• Exertise 
These factors determin,e how well the bones 
form in early adulthood (peak bone mass,). 
After this, prevention of bone loss becomes, 
the rnost important. Anxthing, which leads 
to decreased fortnatron of bcme early in life, 
or foss of bone structure later in life, may 
lead to osteoporosis and (rag·iJe boi:ies. which 
can then fractute. 
Who- is at risk? 
Riskfactors are·similar in men and women: 
• Advanced age 
• Family 'hislor,y 
• Small or thin build 
• Low levels of 6esfrogen (women) or 
testosterone (men) 
,• Low calcillrn and vitamin D intake 
and/or absorption 
• Physical inactivity or exeessive exercise 
• Taking Corticosteroids, Thyroid 
Medications, AnticonvuJS'ahts or 
Anticoagulants 
• Smoking 
• Excessive afcohol and caffeine 
., Chronic diseases of kidney, lung. 
stomach and intestit1es 
" Early menopause 
Appendix 12 
Pharmacist survey 
(Part Ila) 
Program to tackle osteoporosis in a rural community 
Please complete this 3-minute anonymous survey and return to the Tasmanian School of Pharmacy in the reply-paid 
envelope provided. Thank you for your assistance. 
1. Were you satisfied with the pharmacist (Mark Naunton) conducting the osteoporosis screening in your 
pharmacy? 
D Unsure 
No, not at all Yes, completely 
2. Did you find the osteoporosis screening in your local pharmacy useful? 
I D Unsure 
Not useful at all Very useful 
3. Do you believe that your patients found the osteoporosis screening useful? 
I D Unsure 
Not useful Very useful 
4. Do you believe that your local doctors found the osteoporosis screening useful? 
D Unsure 
Not useful Very useful 
5. Do you believe pharmacists can assist doctors identify patients at risk of osteoporosis? 
D Unsure 
No, not at all Yes, most definitely 
6. Did you encounter any problems/difficulties with patients following the screening that was as a direct 
result of the screening or the pharmacist's advice to your patient? 
YES - please state what ................................................................ . 
NO 
7. Please make any comments regarding the osteoporosis screening (use back page if required) 
Appendix 13 
GP survey 
(Part Ila) 
Program to tackle osteoporosis in a rural community 
Please complete this 3-minute anonymous survey and return to the Tasmanian School of Pharmacy in the reply-paid 
envelope provided. Thank you for your assistance. 
1. Were you fully informed of the project prior to its commencement? 
D Unsure 
No, not at all Yes, completely 
2. Did you receive adequate feedback (by letter or phone) from the pharmacist conducting the screening? 
I D Unsure 
Not adequate at all More than adequate 
3. Do you believe that your patients found the osteoporosis screening useful? 
I D Unsure 
Not useful Very useful 
4. Did you find the osteoporosis screening in your local pharmacy useful? 
D Unsure 
Not useful at all Very useful 
5. Would you support more widespread use of osteoporosis screening in pharmacies if the pharmacist is 
adequately trained and there are specific guidelines to follow? 
I D Unsure 
Not support at all Strongly support 
6. Do you believe pharmacists can assist doctors identify patients at risk of osteoporosis? 
D Unsure 
No, not at all Yes, most definitely 
7. Did you encounter any problems/difficulties with patients following the screening that was as a direct 
result of the screening or the pharmacist's advice to your patient? 
YES - please state what ................................................................ . 
NO 
8. Please make any comments regarding the osteoporosis screening (use back page if required) 
Appendix 14 
Subject satisfaction survey 
(Part Ila) 
Questionnaire 
Please circle your response to the following questions 
1.Did you find the osteoporosis screening useful? 
Yes - it helped a great deal 
Yes - it helped somewhat 
No - not really 
No - not at all 
Unsure 
2. Has the information and other services you received from the pharmacist helped? 
Yes - They helped a great deal 
Yes -They helped somewhat 
No - Not really 
No- Not at all 
Unsure 
3. Did you speak to your doctor about osteoporosis following the screening in the 
pharmacy? 
Yes 
No 
I can't remember 
4. If you answered NO in question 3, please circle why? 
I forgot to speak to my doctor 
I didn't think it was important to discuss with my doctor 
I didn't want to bother my doctor 
I thought my doctor would get upset 
I have not seen my doctor 
Other reason 
5. Did you speak to your usual pharmacist about osteoporosis or osteoporosis 
medications after the screening? 
Yes 
No 
I can't remember 
6. Did your doctor investigate your bones further (e.g. another bone scan or X-ray)? 
Yes 
No 
I don't know 
7. Did you make any dietary or lifestyle changes following the osteoporosis screening? 
Yes - please state what- Increased dairy (milk, yogurt, cheese) food intake 
Increased my level of exercise 
Reduced my alcohol or caffeine intake 
Reduced or stopped smoking 
Other - please state what ................................... . 
8. Have you commenced any new medications for your bones, following the heel 
ultrasound screening? (e.g. calcium or vitamin D supplements) 
Yes - Please state what - ................................................................. . 
No 
I don't know 
9. Do you think this service should be available in pharmacies to all women over 65 years 
of age? 
Yes 
No 
Unsure 
10. Would you be willing to pay for this service? 
Yes 
No 
Unsure 
11. If you were willing to pay for this service, how many dollars would you be willing to 
spend? 
12. How would you rate the quality of the service that you received from the pharmacist 
(Mark Naunton) who performed the osteoporosis screening? 
I can't remember 
Poor 
Good 
Very good 
Excellent 
13. Do you feel that your doctor was happy with the screening procedure being 
performed? 
Yes - definitely 
Yes - I think so 
No - I don't think so 
No - definitely not 
Unsure 
14. The following statements require a true or false answer only (please tick box) 
True False 
One in two women and one in three men over 60 will develop an 
osteoporotic fracture 
A family history of osteoporosis is not a risk factor for osteoporosis 
An early menopause, such as after a hysterectomy, is not a risk factor 
for osteoporosis. 
A lifetime low intake of calcium will increase the risk of osteoporosis 
Smoking is not a risk factor for osteoporosis 
Thin women are more often affected by osteoporosis than heavy women 
Weight bearing exercise such as walking can help prevent osteoporosis 
After age 40, it is too late for people to increase their calcium intake to 
prevent osteoporosis 
After menopause, osteoporosis may be slowed down by taking 
oestrogen 
All individuals lose bone mass after 40 years of age 
Normally bone loss slows down after menopause 
A diet high in calcium throughout life can help prevent osteoporosis 
Post-menopausal women need about 1000-1500mg of calcium each day 
Dairy products are a major source of calcium 
It is normal for bone loss to continue throughout life 
Active women are at higher risk for osteoporosis than inactive women 
Alcohol abuse is not linked to the incidence of osteoporosis 
15. Do you have any further comments? (use back of page if required) 
Appendix 15 
Subjects' comments 
(Part Ila) 
1. "living in a rural area and having a husband with a back injury and can't stand driving 
for any length of time, it is not often we get to Hobart, and it was good to be able to just 
get into Cygnet and have the osteoporosis test done there. Thank you." 
2. "When it comes to increasing ones calcium intake by consuming additional dairy 
products I think further advice is required. Trying to drink a litre or more of skinny milk 
a day is a tall order, but advice on suitable cheeses would be helpful (seeing that so 
many are high in saturated fats and salt), and ice creams are usually heavily laced with 
sugar and/or fats (even vegetable fats). It's a catch 22 situation. 
Since participating in this study I have been approached not only by Arthritis Tasmania 
but by other medical charities for donations or to buy raffle tickets. Is this a coincidence 
or has my name and address some how been given out and got distributed, because I 
object to this home invasion as it were, however it has come about." 
3. "I think there should be more information for people to know more about osteoporosis. 
I have probably had osteoporosis a long time. The first time I broke my wrist about 9 
years ago and I didn't know about osteoporosis then. I only know this now." 
4. "Dr said he was pleased with result and glad I had it done." 
5. "Dr hadn't seen results when I visited." 
6. "good job well done." 
7. "Dear Mark, I have had 3 ribs cracked, a couple broken. Dr had them exercised (sic) 1 
month ago, I have not heard from him with my results. Dr X::X:X: told me by falling will 
not and by breaking bones, will not help getting correct medication." 
8. "I have probably got heaps of answers wrong but it is how I feel after being made aware 
of how low my calcium intake was and how much more alive I feel after going to the 
gym - I am now definitely not a couch potato - thank you for making me aware of a 
serious health problem." 
9. "I now use low-fat milk." 
10. "I would have preferred the actual test to have taken place more privately and not in the 
main pharmacy. I was happier doing the questionnaire in the back room of the 
pharmacy." 
11. "I would recommend the screening procedure that you conducted at Bartlett's Pharmacy 
as it would help some women who perhaps hadn't realised they were at risk of having 
osteoporosis." 
12. "I have spoken to him (my doctor) previously, and he said he wasn't interested as he did 
not believe in this test. 
Doctors need to pay more attention to this. Any information has been requested by 
myself and not suggested by the doctor. They will ask you if you smoke or drink but not 
what your calcium intake is!!! I asked for a bone scan but was refused." 
13. "Thank you for having new young people to help us with our health." 
14. "Sorry I have taken so long answering this but I have been layed (sic) up with a really 
bad back- seems to be getting better now." 
15. "Why not earlier than 65?" 
16. "I feel that I don't need this service again- too old." 
17. "Hi there Mark - I enclose herewith questionnaire duly answered ...... Dr X::X:X: asked 
me if I would like to receive the Actonel newsletter, and I agreed to that, and they have 
been quite helpful. They were going to telephone regularly to see how things were 
progessing, but as I am out so often - round the stock or in the garden, or vegetabloe 
paddock, I said I would call them if it were necessary. I was not pleased to note that 
Actonel is manufactured by A ventis, the GM people, who are alleged to have been in 
breach of state regulations regarding escape of GM canola pollens ... I hope you will 
contact me again if you are ever in the Deloraine area. I enjoyed our meeting, even 
though the outcome was somewhat devastating to me." 
18. "I have read that taking bananas and fruit prevent loss of calcium. I eat a banana almost 
everyday at breakfast." 
19. "This has enabled me to talk more about the need to prevent osteoporosis e.g. diet etc." 
20. "Screening for osteoporosis for women over 65 should be covered by medicare as it 
would make sure women received treatment and dietary advice before major damage 
had been done to bones etc. This would save money in the long run because medical 
and hospital bills would be for less and more women would be in better health and more 
active." 
21. "There should be more attention at home, school and TV about good health, good 
eating habits, outdoor activity and food preparation and less on pick up food on the 
run.'' 
22. "calcium - suspect it is connected to depression." 
23. "increased leafy greens, nuts, takini." 
24. "I am unsure how often tests should be undertaken. My Dr said one is not enough and 
should have several. I am on HRT but will endeavour to further reduce my oestrogen 
and will increase my yoghurt and reduce alcohol." 
25. "I recently had the experience of my husband telling me his sister who had recently 
been confmed to a wheel chair and on strong pain killers because her bone structure has 
collapsed - she didn't know she was supposed to take some form of calcium 
supplement, thought it was only for growing children - Hence I feel theres further need 
for education and probably the pharmacy is a good place to start, as a number of people 
don't go to doctors which she didn't till it was too late, but many go to the pharmacy for 
over the counter medicine." 
26. "It is good to have the bone density test come to country towns as it is not always 
possible or convenient for people to get to the city - also a lot of people (pensioners) 
cannot afford a large sum of money to have their bones tested, and if you are a high risk 
person you can make changes to your lifestyle. Thank you for this service." 
27. "My talk on osteoporosis with Mark was very informational for me and I learnt a great 
deal." 
28. "The whole service may be more beneficial if it was started on a younger age." 
29. "Haven found since taking calcium my hair has improved - its thickened, lost dryness 
and is quite shiny also instead of brittle finger nails and toe nails they are quite soft and 
easy to cut and grow rapidly. I also walk for an hour a day now." 
30. "thanks for taking the initiative to do this survey and I do hope you do well in your 
PhD. We need great thinkers." 
31. "I walk 3/4-1 hour four times a week now." 
32. "when having an X-ray, discovered I had osteoporosis fracture of the spine, then doctor 
prescribed medication." 
33. "I was very happy when I found that the study was being conducted .... Since the study I 
have increased my walking, I play indoor bowels once a week and apart from about 40 
minutes daily walking my dog I also walk about 1 hour twice a week. Instead of sitting 
on my ride on mower to cut grass I have bought a 4-stroke lawn mower. I live on a rural 
property so theres a lot of grass to cut. I attended an information session run by the 
council for the ageing and if they start exercise classes I will participate." 
34. "Since I had this test I have had anaemia problems causing some angina. I was admitted 
to hospital and given blood transfusions. I have been more concerned with blood levels 
than calcium. Low levels causing tiredness etc affected my walking activities." 
35. "Have increased lite milk intake. Included yoghurt or custard daily. Increased sardine 
and salmon weekly. Increased silver beet weekly. Exercise 3 kilometres daily on 
exercise bike." 
36. "Mr Naunton was very helpful in everything he did." 
37. "Very happy with the service I received." 
"Detailed answers were given to all my questions." 
"Explanations given at every step of the procedure." 
"Very much worth pursuing throughout the community - all should take advantage of 
the offer." 
38. "I took the first one of the four Fosamax and I thought I was going to die, I could not 
take any more of them." 
39. ''Had spinal exray (sic), Dr told to drink more milk, eat cheese, yoghurts to bump up 
calcium intake. Haven't got results of exray (sic) she would call if any serious 
problems." 
40. "I came away from the testing feeling better from just talking to Mark." 
41. "I feel the follow-up 'phone call was very beneficial in that I could discuss any changes 
I had made with mark and hear his opinion." 
42. "Stopped taking Caltrate (causing constipation) - noticed nails were breaking and not 
growing as well. Will try again." 
43. "I was diagnosed with osteopaenia. But my calcium reading is 2.7 at the moment. My 
vitamin D is 39 showing I have primary hyperparathyroidism. I am still having the 
calcium levels read every 2 weeks for a while and if they (levels) rise I will have to 
have an operation. All this from an osteoporosis screening done in the local chemist." 
44. "As a pensioner I appreciated not having to pay." 
45. "Why are not (sic) women advised to take calcium when they are going through 
menopause or after hysterectomy by their doctors?" 
46. "Thank you." 
Appendix 16 
GPs' comments 
(Part Ila) 
1 "Patients with severe risk refused any treatment so no one was treated." 
2 "2 screenings were performed on patients that I had referred to the 
Menzies Centre "because they were both high risk, as a result neither of 
them have had screening performed- when I believe it would have been 
preferable." 
3 "Practically, we first screen who is eligible for treatment before bone 
densitometry as PBS criteria are strict - diet assessment regarding 
calcium intake is helpful" 
4 "Education key role - risk factor identification and then screening -
Menzies centre screening preferred over pharmacy screening." 
5 "Trouble is - all patients identified at risk tend to need formal DEXA 
testing anyway." 
6 "Very well received project and mark was very professional and 
pleasant." 
7* "Unrealistic expectation with regard to possible treatments." 
8* "nothing significant." 
9 "Heel ultrasound doesn't always correlate well with DEXA 
assessment." 
10 "People pay money for one heel screening. It provides a guide only. 
They then need to pay again to have a diagnostic BMD done and maybe 
an x-ray to look for a fracture. It adds to the cost for little benefit. They 
would be better to be advised to talk to their doctor about diagnosis 
(BMD and X-ray) for fractures and appropriate prevention e.g. 
exercise." 
11 "Most patients didn't return to us for follow-up and hence being chased 
to see what we had done with patients is inappropriate." 
12* "No PBS supported prescription options causes anxiety and illness 
behaviour." 
Don't do it unless you supply prospective studies and treatment options 
that is affordable." 
13 "I would think the guidelines (for screening in pharmacies) would 
indicate inclusion of referral for more definite densitometry especially 
for equivocal and positive cases." 
14 "Although there are some limitations with heel ultrasound and 
screening in general, I found this service beneficial to me and my 
patients." 
Appendix 17 
Pharmacists' comments 
(Part Ila) 
1 "Excellent project - follow-up with a younger target group would be a 
bonus" 
2 "Project was very useful, time constraints were perhaps the only 
drawback. Only other potential problem was highlighted by a lady who 
was very confused by a similar survey. I believe this just emphasizes the 
need to be vigilant when explaining the results of the screening. In this 
case I think that was done very well by Mark." 
3 "Was very impressed with Mark's professionalism and the way in which 
he involved the pharmacy and pharmacy staff in the process." 
4 "Very happy with service and would like to do again." 
5 "Osteoporosis screening/patient education etc when done as 
professionally and thoroughly as this programme would be far too time 
consuming for the average pharmacy/ist to conduct." 
6 "Screening very useful, but the combination of extensive counselling 
(diet and lifestyle modification) dramatically increased patient 
satisfaction and improved health outcomes." 
7 "There should be more of this type of preventive approach to chronic 
disease management implemented in community pharmacies. Mark was 
fantastic, all my staff loved him, especially all the old women." 
Appendix 18 
Data sheet 
(Part lib) 
Corticosteroid Therapy - RHH Data Sheet 
1. Personal/Demographic Data 
Study Number: 
Admitting Unit: 
Age: 
Smoking history: 
Diagnosis on admission: 
Admission date: 
2 Medical/Surgical history 
Previous fracture? 
If yes, was it while on corticosteroid therapy? 
Documented Osteoporosis? 
3 Medication history 
3.1 ADMISSION 
Corticosteroids 
Oral mg/day 
prednisolone/prednisone 
dexamethasone 
other 
UR Number: 
1-
Sex: Male/Female 
Alcohol intake: 
Weight (ifrecorded): 
Discharge date: 
Inhaled 
Yes/No 
Yes/No 
Yes/No 
beclomethasone 
budesonide 
fluticasone 
other 
mcg/day 
Other medications 
Drug Dose Route Frequency 
Is the patient receiving any medication that can increase the risk or worsen osteoporosis ? 
Dru2 Use Yes No 
phenytoin/carbaniazepine/valproate 
loop diuretics 
cyclosporine 
thyroxine 
Concurrent medications that increase the risk of falls ? 
Dru2 Yes No 
antihypertensives 
tricyclic Antidepressants 
anti-Parkinson' s 
benzodiazepines 
opiates 
Drugs to prevent corticosteroid-induced osteoporosis? 
Dose Yes No 
calcium supplement 
vitamin D supplement 
Hormone Replacement Therapy oral 
transdermal 
other 
raloxifene 
bisphosphonates alendronate 
etidronate 
other 
calcitriol 
calcitonin 
anabolic Steroids 
3.2 DISCHARGE 
Corticosteroids 
Oral mg/day Inhaled mcg/day 
prednisolone/prednisone beclomethasone 
dexamethasone budesonide 
other fluticasone 
other 
Other medications 
Drug Dose Route Frequency 
Is the patient receiving any medication that can increase the risk or worsen osteoporosis? 
Dru2 Use Yes No 
phenytoin/ carbamazepine/valproate 
loop diuretics 
cyclosporine 
thyroxine 
Concurrent medications that increase the risk of falls? 
Drug Yes No 
antihypertensives 
tricyclic antidepressants 
anti-Parkinson' s 
benzodiazepines 
opiates 
Drugs to prevent corticosteroid-induced osteoporosis? 
Dru2 Dose Yes No 
calcium supplement 
vitamin D Supplement 
hormone replacement therapy oral 
transdermal 
other 
raloxifene 
bisphosphonates alendronate 
etidronate 
other 
calcitriol 
calcitonin 
anabolic Steroids 
Assessment of risk factors: 
Risk factor Yes No 
1 Age (>65 years) 
2 Previous Osteoporotic fracture 
3 Family History 
4 Hypogonadism (early menopause) 
5 Smoking 
6 Alcohol intake(> 2 standard drinks/day) 
7 Low body weight (frailty) 
Indication for corticosteroid therapy 
Indication Yes No 
Asthma 
COPD 
Rheumatoid arthritis 
Leukaemia/lymphoma 
Ulcerative colitis 
Inflammatory condition of the eye - specify: 
Inflammatory conditions of the skin - specify: 
Other (specify) 
If RA, has the patient ever taken any Disease-modifying antirheumatoid drugs? Yes/No 
(e.g., methotrexate, gold compounds, sulphasalazine, chloroquine, hydroxychloroquine) 
Duration of corticosteroid therapy 
Duration (months) 
Oral Corticosteroids 
Inhaled Corticosteroids 
Other (nasal, topical) 
Monitoring 
Bone mineral density testing performed in hospital this admission or during another admission within past 
12 months? 
Yes/No 
Result and date, if tested: 
Result Date 
Dual X-ray Absorptiometry (DEXA) 
Appendix 19 
Letter to GP 
(Part lib) 
Dear Dr 
CORTICOSTEROID-INDUCED OSTEOPOROSIS 
The Tasmanian School of Pharmacy, Faculty of Health Science at the University of Tasmania is embarking on a 
project to assist in the prevention of corticosteroid-induced osteoporosis. 
There is no doubt that osteoporosis is a major health issue. Corticosteroid-induced osteoporosis is also an important 
issue - it is the most common type of secondary osteoporosis and accounts for about 20% of all cases of osteoporosis. 
Corticosteroids double the risk of fractures of the hip and distal radius, and at least quadruple the risk of vertebral 
fracture. Estimates of fractures during long-term systemic corticosteroid therapy range from 30% to 50%. 
We recently reviewed 212 consecutive patients admitted to the medical wards of the Royal Hobart Hospital and 
receiving treatment with either oral or inhaled corticosteroids.1 It was determined that: 
• Almost one-third (31 %) of the patients receiving oral corticosteroid treatment had been taking the 
equivalent of 7 .5mg prednisolone daily for at least 6 months. 
• Only 31 % of those who had been taking oral corticosteroids for at least one year were receiving 
medication for osteoporosis prevention. 
• Only 24% of patients taking more than 15mg of prednisolone equivalent/day were receiving 
osteoporosis prevention therapy. 
• Only 16% of women over 45 years of age and on continuous oral corticosteroids were taking 
hormone replacement therapy. 
• Only 6% of the patients receiving oral corticosteroid therapy were on calcium supplements, and no 
patients were receiving additional vitamin D. 
• Only 40% of patients taking the equivalent of 7.5mg prednisolone daily for at least 6 months had 
undergone a bone mineral density test. 
We ask that you read and consider the enclosed information. The guidelines are based on several recently published 
research papers and reviews on the prevention and treatment of corticosteroid-induced osteoporosis, and similar 
guidelines from the UK and USA. The guidelines have been formulated in consultation with Rheumatologist 
Associate Professor Graeme Jones, and have been peer-reviewed by other local Rheumatologists and 
Endocrinologists. 
Our project pharmacist, Mark Naunton, will be in contact with you shortly to arrange a convenient time to visit and 
briefly discuss the material with you. Any queries can be directed to Mark (phone: 0408 993 068). 
This project has been approved by the Research and Ethics Committees of the Southern Tasmanian Acute Care 
Program. The Southern Tasmanian Division of General Practice is also aware and supportive of the project. 
Yours sincerely 
Mark Naunton 
Project Pharmacist/PhD student 
TASMANIAN SCHOOL OF PHARMACY 
Gregory Peterson 
Professor of Pharmacy 
TASMANIAN SCHOOL OF PHARMACY 
Hougardy DMC, Peterson GM, Bleasel MD, Randall CTC. (2000). Is enough attention 
being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 25: 227-34. 
Graeme Jones 
Associate Professor 
MENZIES CENTREIRHEUMATOLOGIST 
Appendix 20 
Letter to pharmacist 
(Part lib) . 
Dear Pharmacist 
CORTICOSTEROID-INDUCED OSTEOPOROSIS 
The Tasmanian School of Pharmacy, Faculty of Health Science at the University of Tasmania is embarking on a 
project to assist in the prevention of corticosteroid-induced osteoporosis. 
There is no doubt that osteoporosis is a major health issue. Corticosteroid-induced osteoporosis is also an important 
issue - it is the most common type of secondary osteoporosis and accounts for about 20% of all cases of 
osteoporosis. Corticosteroids double the risk of fractures of the hip and distal radius, and at least quadruple the risk of 
vertebral fracture. Estimates of fractures during long-term systemic corticosteroid therapy range from 30% to 50%. 
We recently reviewed 212 consecutive patients admitted to the medical wards of the Royal Hobart Hospital and 
receiving treatment with either oral or inhaled corticosteroids.1 It was determined that: 
• Almost one-third (31 % ) of the patients receiving oral corticosteroid treatment had been taking the 
equivalent of 7 .5mg prednisolone daily for at least 6 months. 
• Only 31 % of those who had been taking oral corticosteroids for at least one year were receiving 
medication for osteoporosis prevention. 
• Only 24% of patients taking more than 15mg of prednisolone equivalent/day were receiving 
osteoporosis prevention therapy. 
• Only 16% of women over 45 years of age and on continuous oral corticosteroids were taking 
hormone replacement therapy. 
• Only 6% of the patients receiving oral corticosteroid therapy were on calcium supplements, and no 
patients were receiving additional vitamin D. 
• Only 40% of patients taking the equivalent of 7.Smg prednisolone daily for at least 6 months had 
undergone a bone mineral density test. 
The project Pharmacist, Mark Naunton, will be visiting General Practitioners and providing them with guidelines 
(see overleaf) on the prevention and treatment of corticosteroid-induced osteoporosis. We are also encouraging 
Pharmacists to identify patients on long-term oral corticosteroids and not receiving preventive therapy to discuss with 
their General Practitioner options in preventing corticosteroid-induced osteoporosis. 
We ask that you read and consider the enclosed information. The guidelines are based on several recently published 
research papers and reviews on the prevention and treatment of corticosteroid-induced osteoporosis, and similar 
guidelines from the UK USA and Australia. The guidelines have been formulated in consultation with 
Rheumatologist Associate Professor Graeme Jones, and have been peer-reviewed by other local Rheumatologists and 
Endocrinologists. 
Mark Naunton will be visiting Pharmacies soon to discuss the project and distribute information for Pharmacists and 
patients presenting to your pharmacy for repeat corticosteroid prescriptions. Any queries can be directed to Mark 
(phone: 0408 993 068). Please bring this letter to the attention of the other Pharmacists working in your Pharmacy. 
The Pharmacy Guild of Australia has approved this project. Thank you for your assistance. 
Yours faithfully 
M~ 
Mark Naunton 
Project PharmacistJPhD student 
TASMANIAN SCHOOL OF PHARMACY 
Gregory Peterson Graeme Jones 
Professor of Pharmacy Associate Professor 
TASMANIAN SCHOOL OF PHARMACY MENZIES CENTREIRHEUMATOWGIST 
1 Hougardy DMC, Peteison GM, Bleasel MD, Randall CTC. (2000). Is enough attention being given 
to the adveise effects of corticosteroid therapy? JC/in Phann 1her25: 227-34. 
Appendix 21 
GP survey 
(Part lib) 
Corticosteroid-induced osteoporosis 
Please complete this 5-minute anonymous suroey and return to the Tasmanian School of Pharmacy in the reply-paid envelope 
provided. Thank you for your assistance. 
1. Was the academic detailing session? 
D Unsure 
Not useful Very useful 
2. Academic detailing is a good way of receiving up-to-date unbiased information. 
I D Unsure 
Strongly disagree Strongly agree 
3. The academic detailing session has reinforced my knowledge about corticosteroid-induced osteoporosis. 
I D Unsure 
Strongly disagree Strongly agree 
4. Prior to the visit by Mark Naunton, I routinely considered osteoporosis preventive therapy in patients prescribed 
long-term corticosteroids 
I D Unsure 
Strongly disagree Strongly agree 
5. Following the visit, I am now more likely to consider osteoporosis preventive therapy in patients prescribed long-
term corticosteroids. 
D Unsure 
Strongly disagree Strongly agree 
6. Which health care provider do you believe is responsible for initiating preventive therapy against corticosteroid-
induced osteoporosis? (please circle) 
D General Practitioner 
D Rheumatologist 
D Doctor initiating corticosteroid 
D Unsure 
7. Gender: Male/Female (please circle) 
8. Year of registration as a medical practitioner: 
9. Please make any comments (use back page if required) 
Appendix 22 
GPs' comments 
(Part lib) 
1 "Informative, interesting and well set out" 
2 ''Fantastic - thank you very much." 
3 ''Flow chart and reprints given are extremely useful - thanks." 
4 "It was quite a useful exercise. I will certainly use Ostelin lOOOIU capsules more 
regularly in the elderly osteoporotic patients." 
5 "Good session, 10 minutes is an adequate time and anymore is counter-productive." 
6 "Helpful." 
7 "Very useful." 
8 "Excellent." 
9 ''Very useful session - thanks." 
10 "Very useful visit. Mark was good to clarify a lot of areas and was also very helpful in 
giving an easy to follow protocol - the cards are a good idea." 
11 "Keep up the idea." 
12 "Good to get unbiased scientific-based information." 
13 "We prefer scientific information from people who are not in the business of trying to 
sell company pharmaceuticals, so I was favourably impressed by this style of 
presentation and delivery of information." 
14 "It is important that all health care providers advise prevention not only to 
corticosteroid users but the general population from youth up." 
15 "Good knowledge- thanks." 
16 "Good presentation - one of my areas of special interest." 
17 "I probably need to watch inhaled corticosteroid users more closely." 
18 "There have been a plethora of surveys GPs are requested to do. I refuse all requests 
now. I am only doing this survey because the pharmacist is Post-grad and in 
Tasmania." 
19 "Very useful. I like the flow charts - laminated copies good for surgery." 
20 "Preventive medicine is beginning to take over general practice.? timeconstraints." 
21 "Good." 
22 "Clear and simple - excellent." 
23 "Well worthwhile." 
24 "helpful, informed and honest." 
25 "Guidelines useful and easy to follow. I like the small card and the information about 
vitamin D interesting and useful." 
26 "Thank you." 
27 "We get a large amount of information from drug companies which is not always 
reliable." 
28 "Thank you - the articles are good to see" 
29 "Very relevant and helpful information presented extremely well." 
30 "I am very grateful indeed for this session with Mark Naunton and it has made me 
more aware of preventive treatments and hopefully curative treatments. I am grateful 
for his research and PR work with us GPs and endorse his efforts. Thank you." 
31 "Unbiased information is extraordinarily valuable. I would be happy to provide time 
for swat on a regular basis." 
32 "This was very useful, we all receive via mail relevant and irrelevant information, but 
face to face information transfer makes me remember it much better. Thanks." 
33 "Useful discussion to reinforce current practices in this area. No new information 
however." 
34 "Thank you Mark." 
Appendix 23 
GP letter of appreciation (i) 
(Part lib) 
~I 
~' 
Tasmania 
CLARENCE COMMUNITY HEALTH CENTRE 
MEDICAL PRACTICE 
Mr. Mark Naunton 
Pharmacist 
Tasmanian School of Pharmacy 
Unhlersity of Tasmania 
GPO Box 252 - 26 
Hobart Tasmania 7001 
Dear Mark, 
DEPARTMENT of HEALTH 
and HUMAN SERVICES 
16 Bayfield Street 
BELLERIVE 
Tas. 7018 
Ph: 62 114504 
Fax: 62 114570 
27 Feb. 02 
Ref: General Practice Osteoporosis Update 
I am writing to say thank you for presenting a session on osteoporosis. 
The verbal and written feedback from the participating GPs showed they 
regarded it as very useful. It's effectiveness is demonstrated in the discussion 
and application in practice of the principles discussed. 
Once again, many thanks for your support. As discussed, please contact Dr. 
Marianne Catchpole {Senior Medical Officer) if you wish to further investigate 
the possibilities of research at CCHC. 
Best regards, 
Dr. Max Sarma 
Medical Officer, CCHC 
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GP letter of appreciation (ii) 
(Part lib) 
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Appendix 25 
Pharmacist survey 
(Part lib) 
Corticosteroid-induced osteoporosis 
Please complete this 5-minute anonymous survey and return to the Tasmanian School of Pharmacy in the reply-paid 
envelope provided. Thank you for your assistance. 
1. Was the academic detailing session? 
D Unsure 
Not useful Very useful 
2. The academic detailing session has reinforced my knowledge about corticosteroid-induced osteoporosis. 
D Unsure 
Strongly disagree Strongly agree 
3. Academic detailing is a good way of receiving up-to-date unbiased information. 
D Unsure 
Strongly disagree Strongly agree 
4. Prior to the visit, I routinely discussed osteoporosis prevention with patients prescribed long-term corticosteroids, 
referring them to their GP if necessary. 
D Unsure 
Strongly disagree Strongly agree 
5. Following the visit, I am now more likely to discuss osteoporosis prevention therapy with patients prescribed 
long-term corticosteroids, referring them to their GP if necessary. · 
D Unsure 
Strongly disagree Strongly agree 
6. Gender: Male/Female (please circle) 
7. Year of registration as a pharmacist: 
8. What is your position in this pharmacy (please tick): 
o Owner 
o Employee Pharmacist 
o Locum Pharmacist 
9. Please make any comments (use back page if required) 
Appendix 26 
Pharmacists' comments 
(Part lib) 
1 "We find it of interest and benefit to us to be involved in any of the 
activities of the School of Pharmacy. Many thanks, Mark." 
2 "Given us more confidence in these activities." 
3 "Fridge magnets are a useful counselling tool." 
4 "I regularly do medication reviews in nursing homes and now in the 
community and I will be looking to reinforce these concerns when 
writing to doctors." 
5 "Excellent, already in place gaining valuable customer trust/respect and 
additional sales. Also enhances image of pharmacy as a health 
provider." 
6 "Academic detailing session during trading period has disadvantages of 
constant interruptions due to customers needs and consultation, 
dispensing of scripts etc and it is difficult to focus your entire 
concentration on the person presenting the information. Overall for a 
brief detailing it did increase awareness of the issue and reminded you 
of the need to counsel in appropriate cases." 
7* "Wonderful to receive any in-store training, particularly with such 
relevant topics - thank you." 
8* "Good to see information related to pharmacists in an unbiased manner 
(as opposed to drug representatives). Short and precise and good idea, 
minimising interruption, but reinforcing important aspects of the 
profession." 
9 "Extremely useful insight into a quite common occurrence in practice 
generally overlooked." 
10 "Very positive session - I feel that it is great to be involving 
pharmacists in such a practical way. Will be interesting to see results." 
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